Patents Examined by Gregory S. Emch
  • Combined use of a vector encoding a modified receptor and its exogenous agonist in the treatment of seizures
    Patent number: 10391145
    Abstract: The invention provides methods and materials for treating a seizure disorder such as epilepsy in a patient which employ a vector encoding a modified receptor, the so-called “DREADD” receptor being characterised by (i) a decreased responsiveness to its endogenous activating ligand (ii) a retained or enhanced responsiveness to an exogenous agonist. The modified receptor is expressed in neurons of a seizure focus in brain of the patient, and an exogenous agonist is administered which activates the modified receptor to reversibly alters the excitability of the neurons in the seizure focus leading to synaptic silencing or other inhibition.
    Type: Grant
    Filed: March 6, 2015
    Date of Patent: August 27, 2019
    Assignee: UCL BUSINESS PLC
    Inventors: Dennis Kaetzel, Matthew Charles Walker, Stephanie Schorge, Dimitri Michael Kullmann
  • Method for decreasing depression-like behavior with connective tissue growth factor (CTGF) inhibitor
    Patent number: 10392435
    Abstract: The methods of the present invention are useful for determining whether an individual has or is at risk of developing an affective disorder by detecting the expression level of connective tissue growth factor (CTGF) in a biological sample. The methods of the present invention are also useful for identifying compounds that modulate (e.g., decrease) the expression level or activity of CTGF. The present invention further provides therapeutic methods that target CTGF for the treatment of an affective disorder.
    Type: Grant
    Filed: December 6, 2017
    Date of Patent: August 27, 2019
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Huda Akil, Stanley Watson, Cortney Turner
  • Quantifying biomarkers for diagnosing and treating schizophrenia, bipolar disorder or major depression
    Patent number: 10386362
    Abstract: The invention relates to a method of differentially diagnosing schizophrenia, bipolar disorder and major depressive disorder.
    Type: Grant
    Filed: January 26, 2017
    Date of Patent: August 20, 2019
    Assignee: Cambridge Enterprise Limited
    Inventors: Sabine Bahn, Emanuel Schwarz
  • Single domain antibodies capable of modulating BACE activity
    Patent number: 10377834
    Abstract: Described are single domain antibodies with a specificity for BACE1. More specifically, described are single variable-domain antibodies derived from camelids that bind to BACE1 and are capable of inhibiting the activity of BACE1. The antibodies can be used for research and medical applications. Specific applications include the use of BACE1-specific antibodies for the treatment of Alzheimer's disease.
    Type: Grant
    Filed: January 16, 2018
    Date of Patent: August 13, 2019
    Assignees: VIB VZW, KATHOLIEKE UNIVERSITEIT LEUVEN. K.U. LEUVEN R&D, VRIJE UNIVERSITEIT BRUSSEL
    Inventors: Bart De Strooper, Els Marjaux, Lujia Zhou, Serge Muyldermans
  • Methods and compositions for delivery of exogenous factors to nervous system sites
    Patent number: 10369192
    Abstract: The present invention relates to treatment methods and methods for sustained delivery of one or more exogenous factors to desired nervous system sites. In certain embodiments, the invention relates to the use of biodegradable microspheres to deliver exogenous factors, such as the morphogenic factor, sonic hedgehog (Shh), to the site of spinal cord injury. In certain embodiments, the Shh-releasing microspheres are administered together with stem cells, which may be spinal cord neural stem cells. In certain embodiments, the invention relates to regrowth of neural cells in both the central and peripheral nervous systems.
    Type: Grant
    Filed: November 12, 2013
    Date of Patent: August 6, 2019
    Assignee: Regenerative Research Foundation
    Inventors: Sally Temple Stern, Natalia Lowry, Jeffrey Stern, Susan K. Goderie
  • In vitro detection of prions in blood
    Patent number: 10359434
    Abstract: A method of screening a blood sample for the presence of prions. The method includes the steps of collecting the blood sample in heparin, contacting the sample with a solution comprising recombinant prion protein (rPrP) and Thioflavin T (ThT), and measuring the resulting ThT fluorescence in the sample. The method can further include the step of freezing and thawing the sample prior to contacting the sample with a solution comprising recombinant prion protein (rPrP) and Thioflavin T (ThT). The method can also include the step of precipitating the prions in sodium phosphotungstic acid (NaPTA) prior to contacting the sample with a solution comprising recombinant prion protein (rPrP) and Thioflavin T (ThT).
    Type: Grant
    Filed: November 7, 2016
    Date of Patent: July 23, 2019
    Assignee: Colorado State University Research Foundation
    Inventors: Edward A. Hoover, Candace K. Mathiason
  • Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
    Patent number: 10301379
    Abstract: The disclosure relates to antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau. The disclosure also relates to diagnostic, prophylactic and therapeutic methods using anti-tau antibodies.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: May 28, 2019
    Assignee: JANSSEN VACCINES & PREVENTION B.V.
    Inventors: Jehangir Wadia, Gabriel Pascual, Robert Anthony Williamson, Katarina Radosevic, Jaap Goudsmit
  • Methods for the treatment of neurological disorders and diseases using FNDC5
    Patent number: 10286042
    Abstract: The invention provides methods for identifying, assessing, preventing, and treating neurological disorders and diseases using Fndc5 and modulators of Fndc5 expression or activity.
    Type: Grant
    Filed: October 1, 2014
    Date of Patent: May 14, 2019
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Bruce M. Spiegelman, Christiane D. Wrann
  • Retro-inverso analogs of spadin display increased antidepressant effects
    Patent number: 10251937
    Abstract: Compositions, pharmaceutical compositions and biodegradable pharmaceutical compositions containing at least one analog of spadin or at least one analog of a propeptides of spadin or mixtures thereof are described. Methods for treating depression using the analogs of spadin or analogs of propeptides of spadin or mixtures thereof, as well as methods for blocking TREK-1 channel activity are also disclosed.
    Type: Grant
    Filed: January 27, 2015
    Date of Patent: April 9, 2019
    Assignees: MEDINCELL, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Georges Gaudriault, Catherine Heurteaux, Jean Mazella, Marc Borsotto, Hamid Moha Ou Maati, Julie Veyssiere
  • Method for measuring toxicity of human CSF
    Patent number: 10232056
    Abstract: The problem is to provide a method that can quickly and efficiently evaluate the toxicity of human cerebrospinal fluid (CSF) with small amounts of human CSF. The problem is solved by a method comprising administering human CSF into the cerebral ventricle of a rodent such as a mouse, and evaluating the cognitive function of the rodent by using a behavioral pharmacological technique.
    Type: Grant
    Filed: April 16, 2015
    Date of Patent: March 19, 2019
    Assignee: KYOWA HAKKO KIRIN CO., LTD.
    Inventors: Shinichi Uchida, Tomoyuki Kanda
  • Preparation methods for a novel generation of biological safe KLH products used for cancer treatment, for the development of conjugated therapeutic vaccines and as challenging agents
    Patent number: 10221220
    Abstract: The present invention relates to the provision of a biologically safe hemolymph sera, preferably hemocyanin, more preferably KLH (keyhole limpet hemocyanin). A method for producing virus free hemocyanin is provided.
    Type: Grant
    Filed: June 12, 2014
    Date of Patent: March 5, 2019
    Assignee: biosyn Arzneimittel GmbH
    Inventors: Ortwin Kottwitz, Thomas Stiefel, Shammana N. Muddukrishna
  • Alzheimer's disease assay in a living patient
    Patent number: 10222368
    Abstract: An assay for Alzheimer's disease (AD) pathology in a living patient is disclosed wherein an amount of ?7nAChR or TLR4 in a FLNA-captured protein complex or ?7nAChR in an A?-captured protein complex or ?7nAChR-FLNA, TLR4-FLNA and/or ?7nAChR-A?42 complex present as a protein-protein complex in a sample is compared to the amount in a standard sample from a person free of AD pathology. An amount greater than in the standard sample indicates AD pathology. Also disclosed is an assay predictive of prognosis for treatment with a medicament in which the amount of an above protein or protein complex is compared to an amount in the presence of a medicament that binds to a FLNA pentapeptide and contains at least four pharmacophores of FIGS. 7-12. An amount of protein or protein complex determined in the presence of the medicament that is less than the first amount indicates a favorable treatment prognosis.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: March 5, 2019
    Assignee: Pain Therapeutics, Inc.
    Inventors: Hoau-Yan Wang, Lindsay Burns Barbier
  • Alpha-synuclein antibodies and uses thereof
    Patent number: 10208111
    Abstract: The invention describes antibodies having a high affinity for aggregated forms of ?-synuclein and a low affinity for monomeric forms of ?-synuclein. The antibodies are useful in the diagnosis of neurodegenerative diseases.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: February 19, 2019
    Assignee: United Arab Emirates University
    Inventor: Omar El-Agnaf
  • Fusion proteins comprising P3 of bacteriophage
    Patent number: 10208090
    Abstract: The invention relates to agents and to pharmaceutical compositions for reducing the formation of amyloid and/or for promoting the disaggregation of amyloid proteins. The compositions may also be used to detect amyloid.
    Type: Grant
    Filed: May 4, 2017
    Date of Patent: February 19, 2019
    Assignee: PROCLARA BIOSCIENCES, INC.
    Inventors: Rajaraman Krishnan, Richard Fisher
  • CSN5 polypeptides and uses thereof for screening therapeutic agents
    Patent number: 10203328
    Abstract: The present invention relates to mutated CSN5 polypeptides and their use in a method of screening modulators of CSN5 activity that could be used as therapeutic agents.
    Type: Grant
    Filed: February 27, 2017
    Date of Patent: February 12, 2019
    Assignee: University of Leicester
    Inventors: Aude Echalier, Christian Dumas, Melissa Birol
  • Biomarkers associated with schizophrenia
    Patent number: 10197580
    Abstract: The invention relates to biomarkers and methods of diagnosing or monitoring schizophrenia, or a predisposition thereto.
    Type: Grant
    Filed: March 9, 2015
    Date of Patent: February 5, 2019
    Assignee: Cambridge Enterprises Limited
    Inventors: Sabine Bahn, Man Kuan Chan
  • Antibody based reagents that specifically recognize neurodegenerative disease related forms of the protein TDP-43
    Patent number: 10191068
    Abstract: The invention relates to antibodies, antibody fragments and binding agents that specifically recognize TDP-43 associated with frontotemporal dementia (FTD), but not TDP-43 associated with amyotrophic lateral sclerosis (ALS) or TDP-43 associated with healthy human brain tissue, and antibodies, antibody fragments and binding agents that specifically recognize TDP-43 associated with ALS, but not TDP-43 associated FTD or TDP-43 associated with healthy human brain tissue.
    Type: Grant
    Filed: February 2, 2015
    Date of Patent: January 29, 2019
    Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
    Inventors: Michael Sierks, Stephanie Williams, Lalitha Venkataraman
  • Micropillar arrays for assaying myelination
    Patent number: 10180423
    Abstract: Micropillar arrays for assaying differentiation of oligodendrocyte precursor cells into oligodendrocytes, ensheathment, and/or wrapping of the micropillars by the oligodendrocytes is provided. Also provided herein are methods of using the micropillar arrays for screening of candidate agents that promote differentiation of oligodendrocyte precursor cells into oligodendrocytes, ensheathment, and/or wrapping of the micropillars by the oligodendrocytes. A system comprising micropillar arrays and oligodendrocyte precursor cells are also provided.
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: January 15, 2019
    Assignee: The Regents of the University of California
    Inventors: Jonah R. Chan, Seonok Lee
  • D-enantiomeric peptides derived from D3 and use thereof
    Patent number: 10167318
    Abstract: The present invention relates to novel D-enantiomeric A-beta-oligomer-binding peptides, homologs, fragments, parts and polymers thereof and use thereof.
    Type: Grant
    Filed: April 10, 2017
    Date of Patent: January 1, 2019
    Assignee: FORSCHUNGSZENTRUM JUELICH GMBH
    Inventors: Dieter Willbold, Susanne Aileen Funke, Oleksander Brener, Luitgard Nagel-Steger, Dirk Bartnik, Antonia Nicole Klein
  • Monoclonal antibody against human PrPc and use thereof
    Patent number: 10155808
    Abstract: A monoclonal antibody against human PrPc protein capable of reducing the expression level of transcription factor Twist1 in a targeting mode and inducing macrophage and NK cells to target to rectal cancer tumor cells. The combined drug therapy with the antibody and cetuximab also exhibits inhibitory effect on tumor better than administration of the antibody or cetuximab alone.
    Type: Grant
    Filed: November 14, 2016
    Date of Patent: December 18, 2018
    Assignee: Institute of Zoology, Chinese Academy of Sciences
    Inventors: Quan Chen, Baowei Li, Haiying Hang, Lei Du, Jun Wang, Xiaohui Wang